Celyad Signs an Exclusive License Agreement with Horizon Discovery for its shRNA Technology
Shots:
- Celyad to get hold of Horizon’s shRNA technology for generation and development of allogenic CAR-T therapies
- shRNA (Short hairpin) technology is based on DNA and contains a selectable marker to allow elimination of cells that didn’t transfected or transduced
- Celyad’s novel CYAD-101 is a non-gene-edited allogeneic CAR-t candidate- NKG2D-based is developed by using the TIM (TCR Inhibiting Molecule)
Ref: Celyad | Image: Awexexportbe
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com
